Angle Signs Commercial Agreement with Large Pharma

Angle signs commercial agreement with Large Pharma to develop Parsortix-based androgen receptor

Overview

Angle plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announced that it has signed a supplier agreement with Large Pharma to develop a Parsortix-based androgen receptor (AR) detection assay for use in prostate cancer studies.

Terms of Agreement

• Under the terms of this agreement, worth £550,000 to Angle, the company will develop a CTC-based AR assay. 
• Assay development will take place in the Angle's UK laboratories, with project completion expected in Q1 2025. 
• A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the company supporting clinical studies.

Androgen Receptor

• Androgen receptor is a nuclear protein involved in cell growth and proliferation, cell cycle progression, protein synthesis, and cell death. 
• The analysis of Parsortix harvested CTCs using the company's AR assay could enable longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow-up.

Comments from Angle

• CEO

CEO of Angle, Andrew Newland commented: ""This is further validation of Angle's Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market. We anticipate that success in this first phase of assay development may lead to much larger contracts for use of the assay in clinical trials.""

• CSO

Angle’s chief scientific officer, Karen Miller commented: ""We are delighted our expertise is being put to use in the isolation, harvest, and profiling of CTCs for androgen receptor investigation with the potential for Angle's assays to be used in clinical trials. The new androgen receptor assay will also be an important addition to the menu of assays we can offer other customers.""

Prostate Cancer

• Prostate cancer is the second most common cancer in men with 1.5 million new cases diagnosed globally each year and 5 million men living with prostate cancer (5-year prevalence). 
• The androgen receptor plays a pivotal role in prostate cancer tumour growth and progression with anti-androgen therapy frequently given as first-line treatment. 
• However, response is variable, and 20-30% of patients go on to develop resistance, resulting in disease progression and the development of metastatic castration resistant prostate cancer (mCRPC), which is currently incurable.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!